Annerley

Researchers are conducting a phase 4, double-blind, randomized, placebo-controlled trial to evaluate the effectiveness of n-acetylcysteine (NAC) in improving treatment outcomes for adults with Alcohol Use Disorder (AUD) in Australia. The study addresses the urgent need for new, evidence-based treatments in AUD, as current medications have limited success and do not consider individual differences such as genetics and coexisting clinical conditions. This trial builds on previous pilot research to test whether NAC can help reduce heavy drinking more effectively than placebo. Participants will receive either 2400 mg per day of NAC or a matched placebo for 12 weeks. The study will include 280 adults aged 18 to 70 years who meet AUD criteria and have a history of heavy drinking. The trial uses a double-blind design, so neither the participants nor the researchers know who receives NAC or placebo during the treatment period. During the study, participants will be closely monitored through research interviews and assessments to evaluate changes in heavy drinking days over 24 weeks. Participants must have stable housing and sufficient cognition and English skills to provide informed consent and complete study procedures. Safety and tolerability of NAC will also be assessed, alongside adherence to treatment and any side effects. The primary outcome is the number of heavy drinking days measured over 24 weeks.